Compare Intel Corp (INTC) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Natera Inc. Common Stock — how do they compare? Intel Corp trades at $95.43 (market cap $543.46B), while Natera Inc. Common Stock trades at $394.16 (market cap $57.03B). The key difference: Intel Corp is far larger — about 9.5× Natera Inc. Common Stock's market cap, and Intel Corp pays a 2.24% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and Natera Inc. Common Stock for 0 Days on average.
| INTC | NTRA | |
|---|---|---|
Market Cap | $543.46B | $57.03B |
Volume | 87,420,405 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $140.94 | $425.64 |
52-Week Low | $33.62 | $179.42 |
Typical Hold Time | 116 Days | 0 Days |
Enterprise Value | $564.27B | $56.18B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $98.12, down 3.19% today, amid mixed technical signals with bearish moving averages but bullish oscillators. Fundamentally, the company shows improving operational trends with three consecutive quarterly EPS beats and positive operating cash flow of $9.70B in 2025, though net income remains negative at -$267M. The stock has surged over 220% year-to-date as investors assess the progress of Intel's foundry turnaround strategy and High-NA chipmaking advancements.
Intel presents a high-risk, high-reward opportunity as the company executes its strategic pivot to a foundry model. While valuation metrics appear stretched with a P/E of 904, analyst consensus targets $111.72 suggesting 14% upside potential. Key risks include intense competition from TSMC and AMD, ongoing negative profitability, and the execution challenges of the foundry transition in a capital-intensive industry.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
